BRIEF-Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin

Reuters

Feb 17

Feb 17 (Reuters) - Compass Pathways PLC CMPS.O:

COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN SECOND PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION
COMPASS PATHWAYS PLC - COMP360 SHOWS WELL-TOLERATED AND SAFE PROFILE
COMPASS PATHWAYS PLC - REQUESTS FDA MEETING FOR ROLLING SUBMISSION

Source text: ID:nBw6fCmxZa

Further company coverage: CMPS.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612599174"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612599174\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612599174?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612599174","market":"nz","top_or_hot":-1,"title":"BRIEF-Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin </title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span>Compass Pathways <a href=\"https://laohu8.com/S/PLC\">PLC</a> <span>CMPS.O</span>:</p><ul><li><p>COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN SECOND PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION</p></li><li><p>COMPASS PATHWAYS PLC - COMP360 SHOWS WELL-TOLERATED AND SAFE PROFILE</p></li><li><p>COMPASS PATHWAYS PLC - REQUESTS FDA MEETING FOR ROLLING SUBMISSION</p></li></ul><p>Source text: <span>ID:nBw6fCmxZa</span></p><p>Further company coverage: <span>CMPS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-17 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin </title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span>Compass Pathways <a href=\"https://laohu8.com/S/PLC\">PLC</a> <span>CMPS.O</span>:</p><ul><li><p>COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN SECOND PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION</p></li><li><p>COMPASS PATHWAYS PLC - COMP360 SHOWS WELL-TOLERATED AND SAFE PROFILE</p></li><li><p>COMPASS PATHWAYS PLC - REQUESTS FDA MEETING FOR ROLLING SUBMISSION</p></li></ul><p>Source text: <span>ID:nBw6fCmxZa</span></p><p>Further company coverage: <span>CMPS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA8KNZBC:1","article_id":"2612599174","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612599174","pubTimestamp":1771328623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin Feb 17 (Reuters) - Compass Pathways PLC CMPS.O:COMPASS PATHWAYS SUCCESSFULLY ACHIEVE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CMPS":"COMPASS Pathways plc"},"translate_title":"BRIEF–Compass Pathways在评估Comp360裸盖菇素的第二项3期试验中成功达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":0.9},"content_text":"BRIEF-Compass Pathways Successfully Achieves Primary Endpoint In Second Phase 3 Trial Evaluating Comp360 Psilocybin Feb 17 (Reuters) - Compass Pathways PLC CMPS.O:COMPASS PATHWAYS SUCCESSFULLY ACHIEVES PRIMARY ENDPOINT IN SECOND PHASE 3 TRIAL EVALUATING COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSIONCOMPASS PATHWAYS PLC - COMP360 SHOWS WELL-TOLERATED AND SAFE PROFILECOMPASS PATHWAYS PLC - REQUESTS FDA MEETING FOR ROLLING SUBMISSIONSource text: ID:nBw6fCmxZaFurther company coverage: CMPS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}